H. Geng

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Depei Wu, Xiaowen Tang, Jin Zhou, 2021, Frontiers in Oncology.

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma

Depei Wu, Meng-jun Shan, Yang Xu, 2022, Frontiers in Immunology.

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma

Kailin Xu, Zhenyu Li, Xiangmin Wang, 2022, Frontiers in Immunology.

Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Depei Wu, Jin Zhou, Ying Zhang, 2021, Blood.

CT radiomics can predict disease progression within 6 months after chimeric antigen receptor-modified T-cell therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma patients.

J. Yan, C. Li, Y. Li, 2023, Clinical radiology.